The drug, Abilify MyCite, has an ingestible sensor embedded into the pill to record when the medication was taken. When the pill is swallowed, the sensor sends a message to a wearable patch, which then transmits information to a mobile app so patients can monitor their medication intake on their phones. Patients can also allow their caregivers and physicians to access the data from the app through an online portal.
Abilify MyCite, manufactured by Otsuka Pharmaceutical Co., is approved for schizophrenia, acute bipolar disorder and adult depression. The sensor technology and patch are made by Proteus Digital Health.
The FDA noted that the drug should not be used to track ingestion in real time, since detection may be delayed.
More articles on supply chain:
AHA urges FDA to address saline bag shortage
6 ways the proposed Republican tax overhaul could impact pharma
FDA Commissioner: Keep defense medical device approvals to us
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
